black and brown leather padded tub sofa

Reprogramming Immune-Cold Tumors

Precision immunotherapies for difficult-to-treat cancers

Explore Our Science

THE CHALLENGE

Immune-Cold Tumor Microenvironment (TME) Resists Today’s Most Powerful Therapies

Yet many solid tumors remain poorly immune infiltrated, profoundly myeloid-suppressed and inadequately primed for durable responses.

Overcoming the immune-cold TME remains a major unmet need in cancer therapy.

Modern cancer therapies can be highly effective. Immune checkpoint inhibitors show profound efficacy in a subset of cancers. Recent advances in antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and CAR-T therapies enable precision tumor killing.

THE SOLUTION

Engineering
Immunity in Context
Create a Target / crosshair → Teal/Cyan: #0A9DB5. Clear background
Create a Target / crosshair → Teal/Cyan: #0A9DB5. Clear background

TABI integrates tumor-directed targeting with potent immune modulation and therapeutic window engineering to create context-dependent TME-reprogramming therapeutics for immune-cold, therapy-resistant cancers.

LOCALIZE

Tumor-targeting antibody — Localize activity within the TME

TABI™ Platform

A tumor-targeted immunocytokine platform engineered to localize potent immune modulation within the TME.

Orange molecular structure model with spherical atoms connected by bonds in a circular web pattern.
Orange molecular structure model with spherical atoms connected by bonds in a circular web pattern.
REPROGRAM
Immunomodulatory cytokine — Activate innate, myeloid and adaptiveimmunity
CONTROL
Therapeutic window engineering — Control activity for improved safety
MOD2

MOD2 applies the TABI platform to anchor a potent immune-modulatory payload within therapy-resistant tumors, designed to establish local innate and antigen-presenting cell-driven immunity and broaden antitumor responses beyond the targeted tumor cell.

Tumor-anchored reprogramming for therapy-resistant cancers

Create a Target / crosshair → Teal/Cyan: #0A9DB5. Clear background
Create a Target / crosshair → Teal/Cyan: #0A9DB5. Clear background
Orange molecular structure model with spherical atoms connected by bonds in a circular web pattern.
Orange molecular structure model with spherical atoms connected by bonds in a circular web pattern.
TUMOR TARGETED
Selective localization to the tumor microenvironment
IMMUNE ACTIVATION

Immune recruitments, reprograms innate, myeloid and adaptive, immunity

SAFETY BY DESIGN
Engineered for a therapeutic window
Immune payload
Tumor
Immune cells
Immune engage
OUR LEAD PROGRAM
Tumor targeting
MOD2 demonstrates early antitumor activity with evidence of TME modulation.

02

ANTITUMOR ACTIVITY
Activity in immune-cold TNBC

Efficacy demonstrated in the aggressive 4T1 syngeneic model.

PROOF OF CONCEPT
Early Validation

01

ENGINEERED ACTIVITY
Enhanced payload activity

Tumor-directed engineering enhances biological activity.

03

EFFECTS TME
Evidence of TME modulation

Reduced tumor angiogenesis, increased granulocytes, and decreased tumor cell proliferation.

Findings are from preclinical studies in experimental models.

© 2025. All rights reserved.

All content is for informational purposes only. Modunai Therapeutics’ investigational programs are not approved for clinical use.

Modunai Therapeutics LLC , Mansfield Bio-Incubator, 241 Francis Ave, Mansfield, MA 02048